Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uptake and biodistribution of 89Zr-ipilimumab in metastatic melanoma
2024-516547-11-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma and cutaneous malignancy, sponsored by Amsterdam University Medical Center. Primary endpoint: Detection of 89Zr-ipilimumab in tumor lesions. Planned start Oct 2024; status: authorised.
02
Drugs
ipilimumab
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on 2024-516547-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516547-11-00.